Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen

Clinical Cancer Research

Volumn 4, Issue 9, 1998, Pages 2245-2251

  Langdon, Simon P ^a   Gabra, Hani ^a   Bartlett, John M S ^a   Rabiaz, Genevieve J ^a   Hawkins, R Anthony ^b   Tesdale, Ann L ^b   Ritchie, Alison A ^a   Miller, William R ^a   Smyth, John F ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); DISEASE MARKER; HISTOLOGY; HORMONAL REGULATION; HORMONE ACTION; HORMONE BLOOD LEVEL; MOUSE; NONHUMAN; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; CELL DIVISION; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEGESTROL ACETATE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031694228     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. McKenna, N. J., Kieback, D. G., Carney, D. N., Fanning, M., McLinden, J., and Headon, D. R. A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma. Br. J. Cancer, 71: 451-455, 1995.
2. Kieback, D. G., Tong, X-W., Konig, R., Korner, W., Blankenburg, K., Agoulnik, I., Runnebaum, I. B., and Atkinson, E. N. A complex of mutations in the human progesterone receptor gene is associated with increased risk of non-familial breast and ovarian cancer but not of uterine cancer. Proc. Am. Assoc. Cancer Res., 37: 250, 1995.
3. Manolitsas, T. P., Englefield, P., Eccles, D. M., and Campbell, I. G. No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer. Br. J. Cancer, 75: 1397-1399, 1997.
4. Rowe, S. M., Coughlan, S. J., McKenna, N. J., Garrett, E., Kieback, D. G., Carney, D. N., and Headon, D. R. Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. Cancer Res., 55: 2743-2745, 1995.
5. Agoulnik, I., Weigel, N., Tong, X-W., Blankenburg, K., and Kieback, D. G. Genetic mutations in the human progesterone receptor gene associated with increased cancer risk lead to a structurally and functionally altered receptor protein. Proc. Am. Assoc. Cancer Res., 37: 222, 1995.
6. Gabra, G., Langdon, S. P., Watson, J. E. V., Hawkins, R. A., Cohen, B. B., Taylor, L., Mackay, J., Steel, C. M., Leonard, R. C. F., and Smyth, J. F. Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer. Clin. Cancer Res., 1: 945-953, 1995.
7. Iversen, O. E., Skaarland, E., and Utaaker, E. Steroid receptor content in human ovarian tumors: survival of patients with ovarian cancer related to steroid receptor content. Gynecol. Oncol., 23: 65-76, 1986.
8. Slotman, B. J., Kuhnel, R., Rao, B. R., Dijkhuizen, G. H., De Graaf, J., and Stolk, J. G. Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival. Gynecol. Oncol., 33: 76-81, 1989.
9. Sevelda, P., Denison, U., Schemper, M., Spona, J., Vavra, N., and Salzer, H. Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma. Br. J. Obstet. Gynaecol., 97: 706-712, 1990.
10. Harding, M., Cowan, S., Hole, D., Cassidy, L., Kitchener, H., Davis, J., and Leake, R. Estrogen and progesterone receptors in ovarian cancer. Cancer (Phila.), 65: 486-491, 1990.
11. Kommoss, F., Pfisterer, J., Geyer, H., Thome, M., Sauerbrei, W., and Pfleiderer, A., Estrogen and progesterone receptors in ovarian neoplasms: discrepant results of immunohistochemical and biochemical methods. Int. J. Gynecol. Cancer, 1: 147-153, 1991.
12. Ahlgren, J. D., Ellison, N. M., Gottlieb, R. J., Laluna, F., Lokich, J. J., Sinclair, P. R., Ueno, W., Wampler, G. L., Yeung, K-Y., Alt, D., and Fryer, J. G. Hormonal palliation of chemoresistant ovarian cancer: three consecutive Phase II trials of the Mid-Atlantic Oncology Program. J. Clin. Oncol., 11: 1957-1968, 1993.
13. Geisler, H. E. Megestrol acetate for the palliation of advanced ovarian carcinoma. Obstet. Gynecol., 61: 95-98, 1983.
14. Rendina, G. M., Donadio, C., and Giovannini, M. Steroid receptors and progestin therapy in ovarian endometrioid carcinoma. Eur. J. Gynaecol. Oncol., 3: 241-246, 1982.
15. Langdon, S. P., Hawkes, M. M., Lawrie, S. S., Hawkins, R. A., Tesdale, A. L., Crew, A. J., Miller, W. R., and Smyth, J. F. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br. J. Cancer, 62: 213-216, 1990.
16. Langdon, S. P., Ritchie, A., Young, K., Crew, A. J., Sweeting, V., Bramley, T., Hillier, S., Hawkins, R. A., Tesdale, A. L., Smyth, J. F., and Miller, W. R. Contrasting effects of 17-β-estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo. Int. J. Cancer, 55: 459-464, 1993.
17. Langdon, S. P., Hirst, G. L., Miller, E. P., Hawkins, R. A., Tesdale, A. L., Smyth, J. F., and Miller, W. R. The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. J. Steroid Biochem. Mol. Biol., 50: 131-135, 1994.
18. Hawkins, R. A., Black, R., Steele, R. J. C., Dixon, M. J., and Forrest, A. P. M. Oestrogen receptor concentration in primary breast cancer and axillary node metastases. Breast Cancer Res. Treat., 1: 245-251, 1981.
19. Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
20. Glasier, A. F., Irvine, D. S., Wickings, E. J., Hillier, S. G., and Baird, D. T. A comparison of the effects on follicular development between clomiphene citrate and its two separate isomers and spontaneous cycles. Hum. Reprod., 4: 252-256, 1989.
21. Serov, S. F., Scully, R. E., and Sobin, L. H. Histological typing of ovarian tumours. International Histological Classification of Tumors, No. 9. Geneva: WHO, 1973.
22. Sikic, B. I., Scudder, S. A., and Ballon, S. C. High dose megestrol acetate therapy of ovarian carcinoma: a Phase II study by the Northern California Oncology Group. Semin. Oncol., 4: 26-32, 1986.
23. Zaino, R. J., Mortel, R., and Satyaswaroop, P. G. Hormonal therapy of human endometrial carcinoma in a nude mouse model. Cancer Res., 45: 539-543, 1985.
24. Satyaswaroop, P. G., Clarke, C. L., Zaino, R. J., and Mortel, R. Apparent resistance of human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor. Cancer Lett., 62: 107-114, 1992.
25. Slotman, B. J., and Rao, B. R. Ovarian cancer (review): etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res., 8: 417-434, 1988.
26. Hamilton, T. C., Behrens, B. C., Louie, K. G., and Ozols, R. F. Induction of progesterone receptor with 17-β-estradiol in human ovarian cancer. J. Clin. Endocrinol. Metab., 59: 561-563, 1984.
27. Jiang, X., Hitchcock, A., Bryan, E. J., Watson, R. H., Englefield, P., Thomas, E. J., and Campbell, I. G. Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res., 56: 3534-3539, 1996.
28. Jiang, X., Morland, S. J., Hitchcock, A., Thomas, E. J., and Campbell, I. G. Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res., 58: 1707-1712, 1998.
29. Vercellini, P., Parazzini, F., Bolis, G., Carinelli, S., Dindelli, M., Vendola, N., Luchini, L., and Crosignani, P. G. Endometriosis and ovarian cancer. Am. J. Obstet. Gynecol., 169: 181-182, 1993.
30. Simpson, B. J. B., Langdon, S. P., Rabiasz, G. J., Macleod, K. G., Hirst, G. L., Bartlett, J. M. S., Crew, A. J., Hawkins, R. A., Macineira-Perez, P. P., Smyth, J. F., and Miller, W. R. Estrogen regulation of transforming growth factor-α in ovarian cancer. J. Steroid Biochem. Mol. Biol., 64: 137-145, 1998.